Trelegy ellipta pack shot with molecules around it
The only choice with 21st century* molecules & evidence of in-class superior components1-5

ICS/LABA: Relvar (fluticasone furoate/vilanterol) vs twice daily ICS/LABA
LABA/LAMA: Anoro Ellipta (umeclidinium bromide/vilanterol) vs Spiolto & improvements vs Bevespi*
LAMA: IncruseEllipta (umeclidinium bromide) vs Spiriva
*Anoro demonstrated improvement on the co-primary endpoint of trough FEV1 while peak FEV1 was similar.

*based on global date of first use

3 molecules and receptor docking

The art of drug design

David Allen, Senior Vice President, Medicine Design, GSK Respiratory R&D, explains how the molecules of Trelegy Ellipta are engineered to last.5-10 Trelegy Ellipta is designed to provide sustained efficacy for patients with COPD.11-13

The art of drug design

David Allen, Senior Vice President, Medicine Design, GSK Respiratory R&D, explains how the molecules of Trelegy Ellipta are engineered to last.2-12 Trelegy Ellipta is designed to provide sustained efficacy for patients with COPD.1,13

The art of drug design

David Allen, Senior Vice President, Medicine Design, GSK Respiratory R&D, explains how the molecules of Trelegy Ellipta are engineered to last.2-12 Trelegy Ellipta is designed to provide sustained efficacy for patients with COPD.1,13

Choose the triple inhaler with 21st century molecules & evidence of in-class superior components.

ICS/LABA

Significant reduction in mean annual rate of moderate/severe exacerbations by 8% (ARR 0.16 95%Cl: 0.11, 15.4; p=0.047) vs. twice-daily ICS/LABAs (of which a high proportion were on Seretide (fluticasone propionate/salmeterol)),2 in a pre-specified sub-analysis of a 52 week open label RCT that compared Relvar vs. GP prescribed usual care*2

In a 12 week double blind RCT vs Seretide, improvement from baseline in lung function (0-24h wmFEV1) was numerically greater with Relvar vs Seretide but this did not reach statistical significance.14

*Analysis based on a subset of patients whose randomisation stratum and pre-randomisation treatment included an ICS and a LABA. Patients could receive a LAMA throughout the treatment period in addition to their randomised treatment

Relvar® (fluticasone furoate/vilanterol) Ellipta pack shot

LAMA/LABA

84mL greater improvement in trough FEV1 from baseline (co-primary endpoint) vs. Bevespi Aerosphere (GLY/FOR)3 & Superior lung function improvement vs. Spiolto Respimat (TIO/OLO)4

84ml difference (162mL vs 78mL) (97.5% Cl: 55,112) while improvement in peak FEV1 within 2 hours of dosing (co-primary endpoint) was similar for both medicines (difference: 3mL)3
In a 24 week, non-inferiority study of Bevespi Aerosphere vs Anoro Ellipta in moderate to severe patients with COPD3
+52mL improvement vs Spiolto in trough FEV1 in a 8 week open-label crossover study {95% CI:28, 77; p=0.001}4

Anoro▼Ellipta (umeclidinium bromide/vilanterol [as trifenatate]) pack shot

LAMA

Superior lung function improvement vs Spiriva Handihaler (TIO)

a difference of 59mL in trough FEV1 at day 85 in the per protocol population (154ml vs 95ml) (95% Cl: 29,88; p<0.001)5

Incruse▼Ellipta (umeclidinium bromide) pack shot

Trelegy’s 21st century molecules are within the optimal range for effective COPD treatment15,16

Empty grass field with flood lights

Not drawn to scale - for illustrative purposes only

What does this mean for your patients?

Prescribing Information Links

Incruse Ellipta prescribing information (PDF)

Relvar Ellipta prescribing information (PDF)

Anoro Ellipta prescribing information (PDF)

Seretide prescribing information (PDF)

Trelegy Ellipta prescribing information (PDF)

Trelegy Ellipta OD is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist.13

Abbreviations

ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.

References:

  1. GSK 50 Years of innovation REF36689
  2. Vestbo J et al N Engl J Med 2016; 375:1253-60
  3. Maltais F et al. Adv Ther 2019; 36:2434-2449
  4. Feldman GJ et al. Adv Ther 2017; 34:2518-2533
  5. Feldman GJ et al. Int J Chron Obstruct Pulmon Dis 2016; 11:719-730
  6. Rossios et al. European Journal of Pharmacology 2011 670: 244-251
  7. Boscia et al. Clinical Therapeutics 2012; 34(8): 1655-1666
  8. Laine DI et al. J Med Chem 2009; 52:2493-2505
  9. Hanania NA. CHEST; 2012;142;119-127
  10. Kempsford et al. Pulm Pharmacol Ther. 2013; 26(2): 256-64
  11. Lipson DA. Adv Ther 2020; 37;4894-4909
  12. van der Palen J. et al. NPJ Prim Care Respir Med 2016; 26:16079.
  13. Trelegy Ellipta SmPC
  14. Relvar Ellipta SmPC
  15. GSK Data on file 2017N335327 REF-2411
  16. Global strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (GOLD) 2021
  17. Feldman GJ et al. Adv Ther 2017; 34:2518-2533
  18. Svedsater H et al. BMC Pulm Med 2013; 13:1-14.
  19. van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079.
  20. Riley JH et al. Int J Chron Obstruct Pulm Dis 2016; 11:1873-1880.
  21. ATS Journal;1971;1-2;The Number and Dimensions of Small Airways in Nonemphysematous Lungs

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

August 2022 | PM-GB-FVU-WCNT-210007 (V4.0)